David W. Denning
Plus aucun poste en cours
Historique de carrière de David W. Denning
Anciens postes connus de David W. Denning
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Stanford University | Corporate Officer/Principal | 01/01/1987 | 01/01/1990 |
| The University of Manchester | Corporate Officer/Principal | 01/01/1990 | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | 01/01/1998 | - |
| Fondateur | 01/01/1998 | - | |
Myconostica Ltd.
 Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 14/09/2009 | - |
| Président | - | 14/09/2009 | |
| Directeur Technique/Scientifique/R&D | 14/09/2009 | - | |
| Fondateur | 14/09/2009 | - |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Etats-Unis | 2 |
| Israël | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectorielle
| Consumer Services | 3 |
| Electronic Technology | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Myconostica Ltd.
Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- David W. Denning
- Expérience
